BTK and COVID-19: In theory, anti-inflammatory drugs aiming at targets such as dihydroorotate dehydrogenase (DHODH), nucleotide-binding domain leucine-rich repeat and pyrin domain containing receptor 3 (NLRP3), Janus kinase (JAK), and Bruton's tyrosine kinase (BTK) [208] can also be used to regulate tissue damage and excessive inflammation caused by COVID-19.